London, United Kingdom, August 12, 2014.

Clinical Accelerator, a full-service clinical contract research organization, is happy to announce the launch of a new clinical study in patients with active ostheoarthritis in collaboration with EuroPharma. The randomized placebo-controlled study will explore the efficacy and safety of EuroPharma’s Curamin® product in patients with hip and knee ostheoarthritis . Curamin® has shown considerable promise in the treatment of osteoarthritis and the study will address the significant current research interest related to establishing the role of the curcumin-based product in the treatment of ostheoarthritis.

About Osteoarthritis:

Osteoarthritis, a degenerative age-related disease that affects the joints, is the most common human musculoskeletal disorder, and a leading cause of disability in elderly populations worldwide. Osteoarthritis treatments presently mainly rely on analgesics, which manage pain, but fail to restore imbalances between catabolic and anabolic processes that underlie the pathogenesis of the condition.

About EuroPharma:

EuroPharma is a one of the leading companies worldwide providing clinically-studied curcumin formulations to address occasional pain and inflammation†, cognitive health, cellular stability, and oxidative damage.* Using highly researched ingredients backed by science, EuroPharma, headquarted in Green Bay, Wisconsin, brings custom, proprietary natural formulas – many well-known in Europe – to the United States and beyond.

†Pain and inflammation due to exercise and overuse.

*THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THESE PRODUCTS ARE NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT DISEASE.

About Clinical Accelerator

Clinical Accelerator is an independent clinical trial management organization operating principally in Central and Eastern Europe, Russia, Ukraine and CIS countries. This vast region has become a hot spot for clinical trials in the last 15–20 years, and provides access to one of the most diverse and available patient populations in the world. The organization offers a broad range of clinical trial services together with a dedicated patient enrolment support to worldwide clients in the pharmaceutical, biotechnology, nutraceutical and medical device industries. Clinical Accelerator’s model of operation is designed to achieve significant cost savings for its clients and to guarantee compact timelines for patient enrolment with a firm focus on the quality of clinical trial data.